Impact of Donor Left Ventricular Hypertrophy on Survival After Heart Transplant

UTAH Cardiac Transplant Program, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
American Journal of Transplantation (Impact Factor: 5.68). 09/2011; 11(12):2755-61. DOI: 10.1111/j.1600-6143.2011.03744.x
Source: PubMed


Left ventricular hypertrophy (LVH) of the donor heart is believed to increase the risk of allograft failure after transplant. However this effect is not well quantified, with variable findings from single-center studies. The United Network for Organ Sharing database was used to analyze the effect of donor LVH on recipient survival. Three cohorts, selected in accordance with the American Society of Echocardiography guidelines, were examined: recipients of allografts without LVH (<1.1 cm), with mild LVH (1.1-1.3 cm) and with moderate-severe LVH (≥ 1.4 cm). The study group included 2626 patients with follow-up of up to 3.3 years. Mild LVH was present in 38% and moderate-severe LVH in 5.6% of allografts. Predictors of mortality included a number of donor and recipient characteristics, but not LVH. However, a subgroup analysis showed an increased risk of death in recipients of allografts with LVH and donor age >55 years, and in recipients of allografts with LVH and ischemic time ≥ 4 h. In the contemporary era, close to half of all transplanted allografts demonstrate LVH, and survival of these recipients is similar to those without LVH. However, the use of allografts with LVH in association with other high-risk characteristics may result in increased mortality.

Download full-text


Available from: Edward M Gilbert, May 07, 2014

  • International anesthesiology clinics 06/2012; 50(3):202-27. DOI:10.1097/AIA.0b013e3182603ead
  • [Show abstract] [Hide abstract]
    ABSTRACT: The evaluation of organ donors is of critical importance in all areas of solid organ transplantation. Donor characteristics have been shown to have robust effects on heart transplant recipient outcomes, and evaluation of the donor for suitability for heart transplantation is therefore very comprehensive. The donor evaluation process is composed of several steps, beginning with the identification of a potential organ donor and ending with the transplantation of a donor heart. The purpose of this review is to dissect the complex process of donor evaluation into its component steps, and to highlight the diverse approaches used by transplant clinicians around the world to optimize outcomes at each step. We provide a summary of donor characteristics that have been associated with increased recipient mortality, and discuss areas of uncertainty. Recent additions to the literature present novel insights and solutions to vexing problems in donor evaluation, such as how to make a more accurate assessment of allograft quality. Continued advancement in the evaluation of donors is essential to maintain heart transplantation as a viable therapy that provides excellent long-term survival for patients with end-stage heart failure.
    The Journal of Heart and Lung Transplantation 11/2014; 33(11). DOI:10.1016/j.healun.2014.05.002 · 6.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Cardiac troponin (cTnI) measured after heart surgery has been associated with increased mortality and morbidity. Data regarding risks and consequences of cTnI release after cardiac transplantation are dismissingly few. This study sought to determine risk factors and prognostic implication of CTnI early levels in a single centre cohort operated on between January 1999 and December 2010. Methods: Data on 362 consecutive recipients (mean age: 47.8±13.7, 20.2% female, 18.2% diabetics, 22.1% with previous cardiac operations, 27.6% hospitalized, 84.9±29.4ml/min preoperative glomerular filtration rate) were analyzed using multivariable logistic regression modeling. Target outcomes were: determinants of troponin release, early graft failure (EGF), acute kidney injury (AKI) and operative death. Results: Mean cTnI release measured 24 hours after transplant was 10.9±11.6 μg/L. Overall hospital mortality averaged 10.8%, EGF 10.5%, and AKI was 12.2%. CTnI release>10 μg/L proved an independent predictor of EGF (OR 2.2; 95% CI, 1.06– 4.6) and AKI (OR 1.031; 95% CI, 1.001–1.064). EGF, in turn, proved a determinant of hospital mortality. Risk factors for cTnI>10 μg/L release were: status 2B (OR 0.35; 95% CI, 0.18– 0.69, protective), length of ischemic time (OR 1.006; 95% CI, 1.001– 1.011), previous cardiac operation (OR 2.9; 95% CI, 1.67-5.0), and left ventricular hypertrophy (OR 3.3; 95% CI, 1.9– 5.6). Conclusions: Postoperative cTnI measured 24 hours after heart surgery is independently associated with EGF and AKI. The search for optimal myocardial preservation is still an issue in contemporary heart transplant.
    PLoS ONE 05/2015; 10(5):e0120813. DOI:10.1371/journal.pone.0120813 · 3.23 Impact Factor